|
COPYRIGHT 2006 Journal of Drugs in Dermatology, Inc.
Treatment of Recalcitrant Atopic Dermatitis with Omalizumab.
Lane JE, MD, et al. Journal of the American Academy of Dermatology. 2006;54:68-72.
Summary
The authors present a case series of 3 patients with recalcitrant atopic dermatitis treated with omalizumab in an effort to evaluate its efficacy and safety in this patient population. For all patients, administration
of omalizumab occurred every 2 weeks. Treatment duration for all patients was 22 weeks. Patient one was a 10-year-old African-American female with atopic dermatitis recalcitrant to emollients, topical corticosteroids, topical tacrolimus, nonsedating and sedating antihistamines, systemic corticosteroids, leukotriene inhibitors, and oyclosporine. Serum IgE level was 1990 IU/mL. Treatment with omalizumab commenced at a dose of 300 mg subcutaneously. At 4 weeks, the dosage was increased to 450 mg and remained there for the duration of treatment. Concurrent medications included trimethoprim-sulfamethoxazole, triamcinolone and tacrolimus ointments, hydroxyzine, and montelukast. During the first 2 weeks of treatment with omalizumab, the patient improved significantly and continued to improve.
Patient 2 was a 13-year-old Caucasian male with atopic dermatitis for 11 years, comprising a body surface area of 80% at initial evaluation. Prior therapies included all of those used in patient one. Serum IgE level was 6120 IU/mL. Treatment with omalizumab began...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
